Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
71 stopped studies mapped to Esophageal Carcinoma and descendants · 94% state a reason
Over the 71 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04949256 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus… | Phase 3 | terminated | Jul 2, 2021 | Merck Sharp & Dohme LLC | Trial was rendered as cancelled work ongoing in the book of business. | Sponsor / business decision |
| NCT06549413 | 18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to… | — | terminated | Aug 12, 2024 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03114319 | Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Apr 14, 2017 | Novartis Pharmaceuticals | Business reasons and not due to any safety concerns | Safety / toxicity |
| NCT06585488 | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… | Phase 1 | terminated | Sep 5, 2024 | BeOne Medicines | The Sponsor has made the decision to terminate this study due to the lack of promising efficacy,… | Efficacy / futility |
| NCT04929015 | Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES… | N/A | suspended | Jun 18, 2021 | Rutgers, The State University of New Jersey | Pending Protocol amendment | Other (stated, no rule matched) |
| NCT02366819 | Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating… | Phase 4 | suspended | Feb 19, 2015 | University of Chicago | Pending data analysis | Other (stated, no rule matched) |
| NCT05312372 | S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With… | Phase 1 / Phase 2 | withdrawn | Apr 5, 2022 | Institut de Recherches Internationales Servier | Strategic development reasons | Sponsor / business decision |
| NCT05462873 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With… | Phase 1 | terminated | Jul 18, 2022 | Novartis Pharmaceuticals | Business decision and not related to safety concerns | Safety / toxicity |
| NCT06560645 | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic… | Phase 1 | terminated | Aug 19, 2024 | Prelude Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT05252416 | (VELA) Study of BLU-222 in Advanced Solid Tumors | Phase 1 | terminated | Feb 23, 2022 | Blueprint Medicines Corporation | This trial was terminated prior to the initiation of Phase 2 for reasons not due to safety concerns. | Safety / toxicity |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT04000529 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected… | Phase 1 | terminated | Jun 27, 2019 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT06420908 | Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal… | N/A | withdrawn | May 20, 2024 | Hebei Medical University Fourth Hospital | The primary reason for termination was difficulty in recruitment | Enrollment / accrual |
| NCT03320629 | A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic… | Phase 2 | terminated | Oct 25, 2017 | Hebei Medical University Fourth Hospital | This study was voluntarily terminated after investigator assessment, with no safety concerns… | Safety / toxicity |
| NCT05834543 | Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined… | Phase 1 / Phase 2 | terminated | Apr 28, 2023 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT05461794 | Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With… | Phase 2 | terminated | Jul 18, 2022 | BeiGene | Due to modification of company strategy. | Sponsor / business decision |
| NCT05067842 | Circulating Tumor DNA (ctDNA) in Locally Advanced Esophageal and Gastroesophageal (GE)…(TRACT DNA) | — | withdrawn | Oct 5, 2021 | Medical College of Wisconsin | Low accrual and PI leaving institution | Enrollment / accrual |
| NCT06494046 | Defining Musical Toxicity and Its Effect on Patient Well-being | — | withdrawn | Jul 10, 2024 | Mayo Clinic | Resident working with study left institution | Other (stated, no rule matched) |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Phase 2 | terminated | Jul 25, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04804696 | Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal… | Phase 2 | terminated | Mar 18, 2021 | Peking University | Several clinical trials had showed that anti-PD-1 agents combined with chemotherapy as neoadjuvant… | Other (stated, no rule matched) |
| NCT06702384 | Molecular Analysis of Gastric and OEsophageal Cancers STudy(MAGnET) | — | withdrawn | Nov 25, 2024 | Royal Marsden NHS Foundation Trust | Never opened to recruitment due to lack of funding | Enrollment / accrual |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT03366012 | Rapid Assessment of Esophageal Adenocarcinoma Risk Test(REACT) | N/A | terminated | Dec 8, 2017 | Columbia University | Product recall | Other (stated, no rule matched) |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With… | Phase 1 | terminated | Sep 13, 2023 | Molecular Templates, Inc. | Sponsor Termination | Other (stated, no rule matched) |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors…(PDL1x41BB) | Phase 1 | terminated | Jan 18, 2019 | Inhibrx Biosciences, Inc | Program terminated due to lack of meaningful efficacy signal. | Efficacy / futility |
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in… | Phase 1 / Phase 2 | terminated | Dec 24, 2020 | BioNTech SE | Sponsor decision | Sponsor / business decision |
| NCT05780736 | A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or…(PROSPECT-ESO) | — | terminated | Mar 23, 2023 | Bristol-Myers Squibb | A decision was made to terminate the study due to expected timelines associated with start-up,… | Enrollment / accrual |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT01307956 | Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or… | Phase 2 | terminated | Mar 3, 2011 | University of Nebraska | Drug manufacturer - Amgen requested study stop, per DSMB observation in POWER trial | Drug supply |
| NCT02530437 | Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With… | Phase 1 / Phase 2 | terminated | Aug 21, 2015 | M.D. Anderson Cancer Center | The sponsor sold the drug TALADEGIB to another company during the trial and thereafter no drug was… | Sponsor / business decision |
| NCT03233724 | Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated… | Phase 1 / Phase 2 | terminated | Jul 31, 2017 | National Cancer Institute (NCI) | Study terminated due to drug supply issues. | Drug supply |
| NCT02344810 | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating… | Phase 1 / Phase 2 | withdrawn | Jan 26, 2015 | Eastern Cooperative Oncology Group | The study did not open to accrual. No start date and no completion dates. | Enrollment / accrual |
| NCT03240679 | Endoscopic Mucosal Resection and Cellular Matrix | N/A | terminated | Aug 7, 2017 | Mayo Clinic | Difficulty obtaining investigational product and study support. | Other (stated, no rule matched) |
| NCT03251417 | Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal… | Phase 2 | terminated | Aug 16, 2017 | Peking University | Because PD-1 antibodies had been proved to be a standard second-line treatment in esophageal… | Other (stated, no rule matched) |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and…(MATILDA) | Phase 2 | withdrawn | Jun 11, 2019 | Gustave Roussy, Cancer Campus, Grand Paris | Similar clinical trials showed not very encouraging results, which made us decide, after several… | Other (stated, no rule matched) |
| NCT04642690 | Nitrates and IL-8 in Barrett's Esophagus | — | terminated | Nov 24, 2020 | Mayo Clinic | could not collect adequate samples | Other (stated, no rule matched) |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT00573131 | Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in… | Phase 2 | terminated | Dec 13, 2007 | Boston Scientific Corporation | OncoGel did not show any impact on overall tumor response | Other (stated, no rule matched) |
| NCT04625543 | Neoadjuvant Immunotherapy to ESCC | Phase 2 | withdrawn | Nov 12, 2020 | Qilu Hospital of Shandong University | insufficient money | Other (stated, no rule matched) |
| NCT03278626 | Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | terminated | Sep 11, 2017 | NYU Langone Health | The study was stopped earlier than anticipated due to slow accrual | Enrollment / accrual |
| NCT03592407 | Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III… | Phase 2 | withdrawn | Jul 19, 2018 | City of Hope Medical Center | Safety concerns | Safety / toxicity |
| NCT05001360 | Study of FMT Combined With Nivolumab in Gastric Cancer | N/A | withdrawn | Aug 11, 2021 | Fujian Cancer Hospital | We could not get the IRB approval. | Other (stated, no rule matched) |
| NCT00003487 | Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow accrual | Enrollment / accrual |
| NCT02272699 | Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable… | Phase 2 / Phase 3 | withdrawn | Oct 23, 2014 | Peking University | Because there are questions about adjuvant radiotherapy in this study, the clinical trial is under… | Other (stated, no rule matched) |
| NCT04084158 | A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced… | Phase 2 | suspended | Sep 10, 2019 | Zhejiang Cancer Hospital | combination arm delevelped significant poor prognosis | Other (stated, no rule matched) |
| NCT00064259 | A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal… | Phase 1 / Phase 2 | terminated | Jul 9, 2003 | National Cancer Institute (NCI) | Discontinued development of G3139 (oblimersen) | Other (stated, no rule matched) |
| NCT02757391 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic… | Phase 1 | terminated | May 2, 2016 | M.D. Anderson Cancer Center | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT02017600 | A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil… | Phase 2 | terminated | Dec 23, 2013 | Nang Kuang Pharmaceutical Co., Ltd. | not stated | Not stated |
| NCT03206125 | NCI UNC Project ESCC | — | terminated | Jul 2, 2017 | National Cancer Institute (NCI) | determined not to be human subjects research | Other (stated, no rule matched) |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer… | Phase 2 | terminated | Feb 14, 2014 | Mayo Clinic | Poor accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 21, 2026source: clinicaltrials